Medical equipment bulls are frequent, 10 years 10 times the shares abound, from the 20-year market to the relevant listed companies research, expected medical equipment leading, the next five years, compound growth rate of more than 20%, higher than the growth of the pharmaceutical sector, belonging to the high-growth plate.
The author focuses on recommending the following four sectors of stocks:
1. cardiovascular implants, the overall market size potential remains, the popularity of the fourth generation of products worthy of attention.
2. Section implants, benefiting from aging and sports popularity, the future market space with high growth, the domestic brand price-performance advantage will help its success.
3. In vitro diagnostics, molecular diagnostics market size is still growing rapidly, chemiluminescence focus on domestic products to improve the technical strength of the market share growth.
4. Large imaging field, belonging to the high-end consumption of CT, MRI future market space growth
DR, color ultrasound and other domestic share of the further increase.
DR: Wan Dong Medical
Ultrasound: Myriad Medical
Gastroscopy: Kai Li Medical South Micro-medicine
Biochemistry: DirecTV
Immunology: AnTuBio, Mike's Bio, TransLife
Molecular: Aide Bio, CapBio
Orthopaedics: DaboCare, Kellettier
Cardiac stents: LPMC
I still recommend four leading stocks in the industry: Myriad Healthcare, a platform company that has become the leader in a number of segments; AnTuBio, a domestic technology leader in the field of chemiluminescence; LPMC, which is the only one that has fourth-generation cardiac stents; KeliMed, a leading ultrasound and endoscopy company; CardioMed, a leading aortic device manufacturer; and NanMicro, a leading gastroscope manufacturer. Medical, gastroscopy leader NanMicroMedicine, orthopedic field leader Dabo medical.
1. Anthem is a leader in chemiluminescence.
AntuBio is the leading chemiluminescence company in China, focusing on the research and development of in vitro diagnostic reagents and instruments, manufacturing, integration and services, the products cover the field of immuno-diagnostics, microbiological testing, biochemical diagnostics, etc., and is able to provide a comprehensive range of product solutions and overall services for the medical laboratory.
Immuno-diagnostic with domestic substitution ability. Chemiluminescence is currently the mainstream technology of immunodiagnosis (the largest segment of domestic in vitro diagnostics), and the market continues to grow rapidly. More than 80% of the domestic chemiluminescence market is monopolized by imported manufacturers, and domestic brands are accelerating import substitution. AnTuBio has considerable advantages in both infectious disease and tumor detection, and is expected to further increase its market share by virtue of its high-quality products and well-established sales network.
Riding on the industry's high-growth wind, with high-quality products and perfect marketing system, AnTuBio's assembly line business is expected to be rapid volume, and become the main driving force of the company's future performance and sustainable growth.
The author expects the company's 2020-2022 net profit to be 9.59, 13.00, 1.698 billion yuan, an increase of 23.9%, 35.6%, and 30.5%, respectively
2.LOPE Medical to build a cardiovascular industry chain.
Leopold Medical is a leading cardiovascular platform company in China with a solid track record. After more than 20 years of integration and optimization, the company has established the cardiovascular field of "devices + drugs + medical services + new medical" four business segments, is China's leading cardiovascular health platform type of enterprise, the cycle of business segments, complementary and synergistic, to ensure that the company's performance is stable and rapid growth.
The company's leading position in the field of cardiovascular stents, innovative products continue to launch. Relying on a number of key technology platforms, LPMC has laid out a large number of innovative products to form a complete echelon in the device segment. In the next five years, the company will usher in the approval of dozens of heavyweight innovative devices, including new balloons, blockers, heart valves, pacemakers, and AI cardiology equipment, which will continue to bring a new incremental increase to the device segment. The company's position as a domestic device leader will be more solidly driven by innovative device products.
In addition to the traditional segments of medical devices and pharmaceuticals, the company also has a broader layout in medical services and new segments in recent years. The company's 20% stake in oncology innovative drug incubation company Lepu Bio, currently in the development of a wealth of products, including PD1, PDL-1, oncolytic viruses, and EFFR, HER2, CD20 and other ADC drug set is in the process of orderly advancement of research and development, the company's future sales in the direction of oncology innovative drugs is worth looking forward to.
The author's profit forecast for the company in 2020-2022 is as follows:
Net profit of 2.25, 2.91, 3.71 billion yuan, a year-on-year increase of 30.4%, 29.4%, 27.5%, the company as a hard-core assets of pharmaceutical innovation and The company as a pharmaceutical innovation hard core assets and leading domestic medical device enterprises, future performance is expected to maintain rapid growth.
3. Dabo Medical, a leading orthopedic company
The company is a comprehensive medical group focusing on orthopedics, neurosurgery, and minimally invasive surgery, and it is a key hi-tech enterprise of the National Torch Program, and one of the competitive orthopedic implant manufacturers in China. The company's main business is the production, research and development and sales of medical high-value consumables, the main products include orthopedic trauma implant consumables, spinal implant consumables and neurosurgical implant consumables, minimally invasive surgical consumables and so on. The company has passed the FDA, CE, ISO13485, GMP and other professional certification, the quality of the products continue to exceed international standards, recognized by domestic and foreign users.
Along with the company's sustained high investment in research and development of new products, the company will gradually from the orthopedic trauma, spine, the advantages of the sub-field, and continue to expand and extend, through the company's own advantages in product research and development
Design of the medical-industrial combination of strengths, as well as sales and service, channel management capabilities. We will continue to enter new fields to build a platform company for high-value consumables and realize long-term steady compound growth.
It is expected that the company's net profit in 2020-2022 will be 586 million yuan, 746 million yuan and 940 million yuan respectively, with a year-on-year growth of 26%, 27% and 26% respectively.
4. Kaili medical ultrasound, endoscopy field leading
Kaili medical for the domestic ultrasound equipment leader, the product line is mainly involved in the ultrasound diagnostic system, electronic endoscopy system and in vitro diagnostic system. The company's leading technology in the field of ultrasound and endoscopy is expected to realize import substitution.
Ultrasound probe technology is one of the core technologies that determine the performance of the ultrasound system, relying on independent research and development, after more than 10 years of efforts in the probe technology, the company has a number of domestic and foreign invention patents. In the field of endoscopy, the company's electronic endoscopy related technology level in the domestic industry in a leading position.
The author expects the company's revenue of 1.44, 1.75, 2.11 billion yuan in 2020-2022, an increase of 11.15%, 23.84%, 23.75%, and the net profit of 125, 266, 342 million yuan, an increase of 93.6%, 35.0%, 25.5%
By Sharewind Saga 8